footandmouth
diseas
fmd
highli
vesicular
diseas
clovenhoof
anim
pose
great
threat
world
economi
diseas
caus
fmd
viru
fmdv
highli
diverg
small
rna
viru
genu
aphthoviru
famili
picornavirida
serotyp
viru
name
c
infect
one
serotyp
produc
immun
serotyp
among
domest
anim
cattl
buffalo
swine
sheep
goat
suscept
diseas
african
wild
buffalo
maintain
sat
serotyp
viru
oropharyng
region
act
carrier
clovenhoof
wildlif
diseas
transmit
via
contamin
air
fomit
direct
contact
infect
anim
infect
viru
replic
rapidli
viremia
occur
within
day
viru
transmiss
occur
day
appear
clinic
sign
gener
fmd
character
format
vesicl
feet
buccal
mucosa
mammari
gland
drool
saliva
form
string
recoveri
affect
anim
retain
viru
oropharynx
may
act
carrier
diseas
transmiss
suscept
anim
fmdv
nm
diamet
consist
singlestrand
positivesens
rna
genom
four
structur
protein
form
icosahedr
capsid
fmd
viral
genom
consist
larg
singl
open
read
frame
orf
flank
highli
structur
untransl
region
utr
utr
divid
five
element
sfragment
poli
c
tract
pseudoknot
cisact
replic
element
cre
intern
ribosom
entri
site
ire
ire
serv
intern
initi
protein
capindepend
manner
utr
contain
short
stretch
rna
fold
specif
stemloop
structur
nucleotid
follow
poli
tract
variabl
length
utr
play
role
viru
translat
rna
replic
orf
translat
singl
polyprotein
subsequ
process
virusencod
proteas
eg
produc
four
structur
eight
nonstructur
protein
protein
selfassembl
form
icosahedr
viruslik
particl
vlp
contain
copi
structur
protein
encapsid
singl
strand
rna
genom
diseas
endem
preval
mani
countri
africa
middl
east
asia
south
america
occur
form
outbreak
india
diseas
caus
serotyp
among
serotyp
preval
current
diseas
control
vaccin
develop
countri
develop
countri
follow
stamp
polici
inactiv
whole
viru
vaccin
wide
use
control
prevent
diseas
howev
prepar
inactiv
viru
vaccin
requir
costli
biocontain
facil
larg
quantiti
live
viru
cold
chain
mainten
associ
risk
escap
live
viru
vaccin
manufactur
unit
environ
vaccin
due
incomplet
activ
also
suitabl
differenti
infect
vaccin
anim
diva
strategi
variou
approach
tri
develop
altern
inactiv
whole
viru
vaccin
vlp
base
vaccin
receiv
lot
attent
consid
one
appeal
approach
contemporari
vaccin
design
due
immunogen
properti
high
safeti
profil
vaccin
deliveri
platform
vlp
gener
use
variou
express
system
like
vaccinia
viru
adenoviru
escherichia
coli
baculoviru
vlp
fmdv
produc
vitro
coexpress
structur
similar
whole
viru
particl
noninfecti
safe
induc
effici
humor
cellular
immun
respons
also
suitabl
diva
strategi
recombin
adenovirus
becom
vector
choic
target
gene
deliveri
express
foreign
antigen
use
gene
therapi
vaccin
cancer
therapi
adenovirus
consid
power
vector
abil
recombin
cultur
high
product
titer
rel
high
capac
transgen
insert
effici
transduct
quiescent
activ
divid
cell
induc
humor
cellular
immun
respons
fmd
molecular
vaccin
base
replic
defici
human
adenoviru
serotyp
carri
fmd
capsid
gene
develop
licens
use
emerg
respons
tool
fmd
outbreak
usa
carri
fmdv
capsid
protein
antigen
along
test
mice
guinea
pig
swine
cattl
protect
homolog
challeng
viru
contain
full
length
report
induc
rapid
increas
fmdvspecif
humor
cellular
immun
respons
compar
origin
vector
henc
consid
fact
studi
carri
construct
character
express
capsid
protein
along
fulllength
wildtyp
andmut
type
fmdv
genet
manipul
produc
recombin
adenovirus
express
fmdv
capsid
protein
carri
obtain
necessari
approv
institut
biosafeti
committe
ibsc
review
committe
genet
manipul
rcgm
depart
biotechnolog
govern
india
human
embryon
kidney
cell
line
agil
technolog
usa
grown
eagl
minimum
essenti
medium
lonza
belgium
contain
fetal
bovin
serum
fb
hepe
nonessenti
amino
acid
lonza
belgium
penicillin
iuml
streptomycin
cell
incub
humidifi
incub
thermo
scientif
usa
viral
rna
fmdv
isol
rneasi
mini
kit
qiagen
germani
convert
cdna
use
thermoscript
rt
invitrogen
usa
per
manufactur
instruct
gene
interest
amplifi
polymeras
chain
reaction
pcr
use
primer
enlist
pcr
perform
use
reaction
mix
contain
phusion
hf
dna
polymeras
neb
usa
phusion
buffer
dntp
primer
pair
templat
cdna
thermocycl
appli
biosystem
usa
pcr
perform
initi
denatur
min
follow
cycl
denatur
anneal
extens
min
final
extens
carri
min
pcr
perform
thermal
condit
except
cyclic
extens
min
final
extens
min
synthesi
carri
two
step
first
step
two
segment
synthes
use
mutagen
primer
enlist
amplif
two
segment
carri
initi
denatur
min
cycl
denatur
anneal
extens
final
extens
carri
min
two
segment
use
templat
synthes
per
pcr
program
pcr
product
purifi
pcr
purif
kit
fermenta
usa
gene
segment
mention
digest
spei
enzym
neb
usa
either
ligat
dna
ligas
thermo
scientif
usa
construct
express
cassett
express
cassett
similar
except
glycin
g
posit
phenylalanin
f
posit
replac
serin
express
cassett
clone
pshuttlecmv
vector
agil
technolog
usa
sali
hindiii
site
flank
cmv
promot
poli
signal
top
e
coli
cell
life
technolog
usa
transform
recombin
pshuttl
vector
transform
top
cell
spreadplat
luria
burtoni
agar
lb
powder
affymetrix
usa
contain
kanamycin
incub
h
top
cell
contain
recombin
pshuttl
vector
kanamycin
resist
grow
lb
agar
contain
antibiot
nonrecombin
top
cell
die
potenti
recombin
coloni
test
goi
coloni
pcr
one
posit
coloni
inocul
lb
broth
contain
kanamycin
incub
shaker
incub
thermo
scientif
usa
amplifi
plasmid
plasmid
isol
plasmid
miniprep
kit
fermenta
usa
per
manufactur
instruct
integr
goi
check
pcr
digest
confirm
sequenc
sequenc
target
gene
carri
autom
dna
sequenc
perkin
elmer
usa
electropor
compet
cell
agil
technolog
use
prepar
chemic
compet
cell
per
protocol
describ
sambrook
russel
recombin
pshuttlecmv
vector
linear
pmei
enzym
neb
usa
use
transform
chemic
compet
cell
gener
recombin
adenoviru
plasmid
homolog
recombin
transform
cell
grown
lb
agar
contain
kanamycin
incub
h
result
coloni
test
goi
coloni
pcr
posit
coloni
grown
lb
broth
overnight
shaker
incub
rpm
follow
plasmid
isol
plasmid
amplifi
cell
grow
teriff
broth
invitrogen
usa
contain
kanamycin
isol
plasmid
midi
kit
qiagen
germani
per
protocol
describ
manufactur
adenoviru
plasmid
digest
paci
enzym
fermenta
usa
transfect
expos
invert
termin
repeat
cell
cultur
well
tissu
cultur
plate
nunc
denmark
h
achiev
approxim
confluenc
transfect
cell
adenoviru
plasmid
plasmid
dna
per
well
perform
use
virapack
transfect
kit
agil
technolog
usa
transfect
cell
observ
daili
day
appear
viru
induc
plaqu
plaqu
appear
earli
individu
pick
care
pellet
centrifug
g
min
cell
resuspend
dulbecco
phosphat
buffer
salin
dpb
contain
ca
mg
freezethaw
thrice
releas
viru
viruscel
suspens
centrifug
g
min
supernat
contain
viru
collect
store
plaqu
deriv
virus
titrat
virus
higher
titer
select
prepar
seed
virus
seed
virus
use
amplif
viru
virus
serial
passag
infect
cell
multipl
infect
moi
indirect
immunofluoresc
assay
perform
detect
express
target
gene
cell
grown
well
tissu
cultur
plate
monolay
infect
recombin
virus
passag
moi
cytopath
effect
cpe
appear
plaqu
infect
cell
monolay
use
immunofluoresc
assay
medium
discard
monolay
wash
twice
pb
air
dri
room
temperatur
cell
fix
chill
acetonemethanol
block
done
incub
cell
bovin
serum
albumin
pb
room
temperatur
min
rabbit
antifmdv
serotyp
serum
dilut
pb
use
probe
express
fmdv
antigen
follow
wash
pb
contain
pbst
cell
stain
alexa
fluor
goat
antirabbit
igg
dilut
pb
unbound
antibodi
remov
wash
pbst
cell
observ
fluoresc
microscop
nikon
japan
antigen
captur
elisa
indirect
sandwich
elisa
also
use
detect
fmdv
antigen
per
protocol
describ
oie
manual
test
sampl
dilut
dpb
test
target
antigen
rabbit
antiserum
antigen
fmdv
use
captur
express
antigen
plate
read
nm
elisa
reader
tecan
usa
absorb
read
background
indic
posit
reaction
consid
neg
serial
dilut
viru
prepar
cultur
media
dilut
ad
well
well
tissu
cultur
plate
follow
addit
cell
prepar
media
contain
fb
plate
incub
incub
day
observ
daili
cpe
viru
titer
calcul
per
method
describ
reed
muench
recombin
adenovirus
purifi
cscl
densiti
gradient
ultracentrifug
two
step
first
clarifi
cell
lysat
contain
adenoviru
layer
cscl
discontinu
gradient
centrifug
rpm
h
ultracentrifug
sorval
wx
ultra
seri
centrifug
thermo
scientif
usa
second
step
adenoviru
obtain
discontinu
gradient
purif
subject
continu
gradient
centrifug
rpm
h
purif
concentr
virus
collect
dialyz
store
cell
monolay
grown
tissu
cultur
flask
nunc
infect
separ
recombin
adenovirus
nonrecombin
replicationdefect
human
adenoviru
avail
ivri
bangalor
moi
virus
allow
adsorb
h
monolay
wash
twice
pb
infect
cell
harvest
h
immedi
adsorpt
everi
h
interv
post
infect
day
frozen
titer
sampl
determin
duplic
mean
valu
use
studi
growth
kinet
adenovirus
cscl
ultrapurifi
recombin
virus
incub
microcentrifug
tube
h
sampl
collect
h
everi
h
interv
frozen
use
viru
titrat
titer
sampl
calcul
duplic
mean
two
valu
use
comparison
elisa
absorb
read
duplic
well
use
calcul
mean
sd
upon
test
express
antigen
collect
variou
time
point
regress
analysi
perform
correl
incub
temperatur
incub
time
use
sa
product
desir
size
bp
bp
detect
agaros
gel
electrophoresi
pcr
product
mutagen
pcr
two
fragment
size
bp
bp
amplifi
subsequ
use
templat
synthes
amplifi
bp
overlap
pcr
coloni
pcr
coloni
screen
found
posit
among
posit
coloni
one
select
amplif
recombin
pshcmv
express
cassett
bp
found
intact
recombin
pshcmv
vector
restrict
enzym
analysi
sequenc
result
provid
confirm
express
cassett
similar
two
desir
induc
mutat
mutant
type
compar
wild
type
parent
genom
growth
transform
cell
lb
agar
result
three
type
coloni
viz
small
intermedi
larg
small
coloni
potenti
recombin
test
goi
coloni
pcr
found
posit
paci
digest
recombin
adenoviru
plasmid
result
two
fragment
size
kb
kb
larger
fragment
repres
linear
adenoviru
plasmid
smaller
one
indic
recombin
transform
cell
took
place
right
arm
origin
replic
xl
adenovir
vector
system
comparison
uninfect
cell
show
visibl
chang
cpe
observ
form
plaqu
earli
day
post
transfect
cell
vector
indic
gener
recombin
adenoviru
adenoviru
gener
post
transfect
express
fmd
capsid
protein
detect
indirect
immunofluoresc
assay
fmdv
typespecif
sandwich
elisa
plaqu
sampl
found
posit
fmdv
type
antigen
elisa
titer
primari
stock
virus
given
plaqu
viru
plaqu
found
contain
highest
viru
titer
among
plaqu
select
amplif
character
virus
viru
titer
approxim
record
supernat
cell
lysat
cscl
purifi
concentr
prepar
recombin
virus
respect
titer
select
virus
passag
given
titer
adenoviru
sampl
obtain
growth
kinet
studi
given
use
draw
viru
growth
kinet
curv
shown
h
post
infect
hpi
viru
detect
infect
sampl
viru
replic
evid
increas
titer
three
adenovirus
could
observ
first
hpi
titer
virus
remain
less
constant
hpi
slight
variat
cpe
complet
day
post
infect
mockinfect
cell
remain
intact
slight
decreas
viru
titer
observ
thermal
stabil
test
titer
recombin
virus
decreas
h
incub
present
demonstr
linear
regress
analysi
show
viru
titer
neg
correl
incub
time
found
statist
signific
p
fmd
import
diseas
transboundari
import
affect
clovenhoof
anim
worldwid
seven
serotyp
fmdv
mani
subtyp
serotyp
crossprotect
make
diseas
control
difficult
serotyp
viru
antigen
poor
compar
serotyp
thu
larg
amount
serotyp
antigen
requir
achiev
level
protect
inactiv
vaccin
vaccin
base
inactiv
whole
virus
emulsifi
adjuv
effect
use
control
prevent
diseas
enzoot
countri
due
sever
limit
inactiv
vaccin
variou
altern
approach
tri
develop
better
vaccin
candid
replicationdefect
human
adenoviru
type
prove
potenti
gene
deliveri
vehicl
basic
express
cassett
fmd
virion
respons
empti
capsid
particl
format
report
induc
rapid
immun
respons
present
studi
incorpor
downstream
express
cassett
provid
two
addit
cleavag
site
besid
increas
genom
size
vector
may
reduc
toxic
infect
cell
demonstr
length
insert
gene
affect
genet
stabil
vector
genom
size
wildtyp
wt
genom
tend
rearrang
achiev
size
closer
wt
genom
may
recombin
packag
cell
line
genom
gener
replic
compet
adenoviru
studi
genom
size
recombin
kb
wt
genom
optimum
genom
packag
wide
believ
wt
toxic
cell
advers
affect
express
recombin
protein
present
studi
reveal
mutat
wt
significantli
affect
viru
titer
express
target
antigen
may
suggest
mutat
provid
replic
advantag
viru
result
demonstr
express
level
target
protein
significantli
correl
viru
titer
pearson
correl
coeffici
depict
studi
involv
electron
microscopi
anim
immun
necessari
confirm
format
empti
capsid
particl
immunogen
potenti
recombin
adenoviru
vaccin
growth
kinet
recombin
virus
less
similar
slightli
differ
viru
particl
seen
hpi
cell
infect
recombin
adenovirus
indic
whole
viru
inoculum
adsorb
viru
particl
eclips
phase
presenc
viru
activ
evid
cell
infect
gener
time
recombin
adenovirus
record
h
h
delay
appear
progeni
virus
cell
infect
recombin
virus
may
due
increas
size
genom
compar
growth
kinet
virus
found
similar
previou
studi
involv
maximum
growth
record
first
h
decreas
later
may
due
unavail
suffici
healthi
cell
round
viru
replic
result
thermal
stabil
virus
agreement
previou
studi
found
statist
signific
less
stabl
compar
recombin
virus
stableat
compar
gener
viru
titer
decreas
h
incub
studi
xue
et
al
demonstr
thermost
decreas
rapidli
recombin
adenovirus
carri
capsid
proteincod
gene
fmdv
gener
amplifi
high
titer
target
protein
effici
express
adenoviru
vector
express
system
test
immunofluoresc
assay
elisa
recombin
adenovirus
exhibit
stabil
h
slight
decreas
titer
studi
vitro
detect
recombin
adenoviru
express
fmdv
empti
capsid
particl
electron
microscopi
anim
immun
necessari
evalu
immunolog
potenti
adenoviru
vector
fmd
vaccin
bp
rk
plan
design
research
work
experi
perform
rk
supervis
bp
sandwich
elisa
statist
analysi
carri
rpt
manuscript
prepar
rk
review
bp
rpt
author
approv
final
manuscript
